145 related articles for article (PubMed ID: 31312426)
1. What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?
Potměšil P
Ther Adv Psychopharmacol; 2019; 9():2045125319855206. PubMed ID: 31312426
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A; Furukawa TA; Salanti G; Chaimani A; Atkinson LZ; Ogawa Y; Leucht S; Ruhe HG; Turner EH; Higgins JPT; Egger M; Takeshima N; Hayasaka Y; Imai H; Shinohara K; Tajika A; Ioannidis JPA; Geddes JR
Lancet; 2018 Apr; 391(10128):1357-1366. PubMed ID: 29477251
[TBL] [Abstract][Full Text] [Related]
3. Evidence-Based Pharmacotherapy of Anxiety Symptoms in Patients with Major Depressive Disorder: Focus on Agomelatine.
Stein DJ
Neurol Ther; 2023 Apr; 12(Suppl 1):13-19. PubMed ID: 37115460
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
Tedeschini E; Levkovitz Y; Iovieno N; Ameral VE; Nelson JC; Papakostas GI
J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
Tundo A; de Filippis R; Proietti L
World J Psychiatry; 2015 Sep; 5(3):330-41. PubMed ID: 26425446
[TBL] [Abstract][Full Text] [Related]
6. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.
Khoo AL; Zhou HJ; Teng M; Lin L; Zhao YJ; Soh LB; Mok YM; Lim BP; Gwee KP
CNS Drugs; 2015 Aug; 29(8):695-712. PubMed ID: 26293743
[TBL] [Abstract][Full Text] [Related]
7. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation.
Fornaro M; Prestia D; Colicchio S; Perugi G
Curr Neuropharmacol; 2010 Sep; 8(3):287-304. PubMed ID: 21358978
[TBL] [Abstract][Full Text] [Related]
8. Second-generation antidepressants for preventing seasonal affective disorder in adults.
Gartlehner G; Nussbaumer B; Gaynes BN; Forneris CA; Morgan LC; Kaminski-Hartenthaler A; Greenblatt A; Wipplinger J; Lux LJ; Sonis JH; Hofmann J; Van Noord MG; Winkler D
Cochrane Database Syst Rev; 2015 Nov; (11):CD011268. PubMed ID: 26558418
[TBL] [Abstract][Full Text] [Related]
9. Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case.
Stuhec M; Oravecz R
Wien Klin Wochenschr; 2016 Apr; 128(7-8):295-8. PubMed ID: 26404738
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
[TBL] [Abstract][Full Text] [Related]
11. Agomelatine: The evidence for its place in the treatment of depression.
Eser D; Baghai TC; Möller HJ
Core Evid; 2010 Jun; 4():171-9. PubMed ID: 20694073
[TBL] [Abstract][Full Text] [Related]
12. A review of preliminary observations on agomelatine in the treatment of anxiety disorders.
Levitan MN; Papelbaum M; Nardi AE
Exp Clin Psychopharmacol; 2012 Dec; 20(6):504-9. PubMed ID: 23088208
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Cipriani A; Zhou X; Del Giovane C; Hetrick SE; Qin B; Whittington C; Coghill D; Zhang Y; Hazell P; Leucht S; Cuijpers P; Pu J; Cohen D; Ravindran AV; Liu Y; Michael KD; Yang L; Liu L; Xie P
Lancet; 2016 Aug; 388(10047):881-90. PubMed ID: 27289172
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of the clinical efficacy and safety of agomelatine with escitalopram in major depressive disorder patients: A randomized, parallel-group, phase IV study.
Urade CS; Mahakalkar SM; Tiple PG
J Pharmacol Pharmacother; 2015; 6(4):198-203. PubMed ID: 26813706
[TBL] [Abstract][Full Text] [Related]
15. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
[TBL] [Abstract][Full Text] [Related]
16. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
17. A Comparative Study of Efficacy and Safety of Agomelatine and Escitalopram in Major Depressive Disorder.
Komaram RB; Nukala S; Palla J; Nambaru LR; Kasturi SM
J Clin Diagn Res; 2015 Jun; 9(6):VC05-VC08. PubMed ID: 26266196
[TBL] [Abstract][Full Text] [Related]
18. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults.
Howland RH
Neuropsychiatr Dis Treat; 2009; 5():563-76. PubMed ID: 19966905
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
